The recent ZORO study comprising 60 women showed no significant difference in amenorrhea between patients treated with or without GnRH agonists [33], whereas the larger POEMS study (257 patients) revealed significantly fewer amenorrhoic patients and more pregnancies among breast cancer survivors in the GnRH agonist group [34]. The gene discussed is GNRH1; the disease is amenorrhea.